122956-28-9Relevant academic research and scientific papers
Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: A novel series of CB1 receptor antagonists
Bostroem, Jonas,Berggren, Kristina,Elebring, Thomas,Greasley, Peter J.,Wilstermann, Michael
, p. 4077 - 4084 (2008/03/12)
A scaffold hopping approach has been exploited to design a novel class of cannabinoid (CB1) receptor antagonists for the treatment of obesity. On the basis of shape-complementarity and synthetic feasibility the central fragment, a methylpyrazole, in Rimonabant was replaced by a pyrazine. The synthesis and CB1 antagonistic activities of a new series of 5,6-diaryl-pyrazine-2-amide derivatives are described. Several compounds showed antagonist potency below 10 nM for the CB1 receptor.
Anti-platelet aggregation activity of some pyrazines
Ohta, Akihiro,Takahashi, Hiromitsu,Miyata, Naoomi,Hirono, Hiroyuki,Nishio, Toyotaka,Uchino, Etsuo,Yamada, Kenji,Aoyagi, Yutaka,Suwabe, Yasushi,Fujitake, Masayuki,Suzuki, Takahiro,Okamoto, Kazuo
, p. 1076 - 1081 (2007/10/03)
This report describes the anti-platelet aggregation activity of 48 pyrazines. Among alkyl- and arylpyrazines tested, 2,3-diphenylpyrazines showed the strongest anti-platelet aggregation activity. Then, various substituents were introduced into the phenyl groups, and the 2,3-bis(p- methoxyphenyl)pyrazine derivatives were consequently found to possess considerably strong inhibitory activity.
